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Abstract The hallmark of adaptive immunity is its ability
to recognise a wide range of antigens and technologies that
capture this diversity are therefore of substantial interest.
New methods have recently been developed that allow the
parallel analysis of T cell reactivity against vast numbers of
diVerent epitopes in limited biological material. These tech-
nologies are based on the joint binding of diVerentially
labelled MHC multimers on the T cell surface, thereby pro-
viding each antigen-speciWc T cell population with a unique
multicolour code. This strategy of ‘combinatorial encoding’
enables detection of many (at least 25) diVerent T cell
populations per sample and should be of broad value for
both T cell epitope identiWcation and immunomonitoring.
Keywords MHC multimers · Combinatorial encoding · 
T cell detection · Epitope mapping · MHC tetramers · 
Quantum dots
Introduction
CD8 T cells of the adaptive immune system are essential to
combat viral infection, intracellular bacteria, and under certain
circumstances, cancer. CD8 T cells utilise their clone-speciWc
T cell receptor (TCR) to recognise cells that display major
histocompatibility complex I (MHC-I) molecules that carry
a disease-associated (e.g. pathogen-derived) peptide. With
the exception of certain immunoprivileged sites, MHC
class I molecules are expressed on the surface of all nucle-
ated cells and consequently, CD8 T cells can survey the
body for intracellular infections or other diseases that alter
the MHC-associated peptide pool. The sequence and hence
speciWcity of the clone-speciWc TCR that each T cell carries
is determined through the rearrangement of the TCRalpha
and TCRbeta loci during T cell development. With an esti-
mated number of 1015 possible TCR gene rearrangements
(i.e. potential combinations of TCRalpha and TCRbeta
chains) [1], the potential TCR repertoire that can be formed
is in fact larger than the size of the human T cell compart-
ment (approximately 5 £ 1011 cells). Consequently, for
most discussions each T cell can in essence be considered
unique.
For the monitoring of antigen-speciWc T cell responses it
is obviously of little relevance to follow total T cell fre-
quencies, but rather frequencies of T cells that can recog-
nise a speciWc antigen should be traced. Over the years, a
variety of assay formats have been developed that monitor
antigen-speciWc T cell responses using functional readouts.
While these assays are of substantial value to measure spe-
ciWc T cell capacities, these assays fail to detect T cells that
lack a particular functional property and consequently can-
not be utilised as a generic tool to measure the frequency of
antigen-speciWc T cells.
The detection of antigen-speciWc T cells independent of
their functional activity Wrst became possible with the dis-
covery that such cells can be stained with Xuorescently
labelled multivalent peptide–MHC (pMHC) complexes.
These recombinant pMHC multimers (somewhat mistakenly
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commonly referred to pMHC tetramers [2]) have over the
past years become an essential tool to dissect the antigen-
reactivity of T cell populations, as for instance shown by
the >2,000 citations to the original paper [3]. However,
until recently, MHC multimer-based Xow cytometry has
been limited to the detection of a single or perhaps two anti-
gen-speciWc T cell populations per sample, and in particular
for clinical samples, this has limited our ability to perform a
comprehensive analysis of disease-associated or therapy-
induced T cell responses.
The development of a number of new technologies over
the past years has brought multiparametric measurement of
antigen-speciWc T cell responses within reach. First, new
technologies for pMHC production allow the generation of
very large collections of pMHC reagents for T cell analy-
ses. Second, both Xow cytometry- and microarray-based
high-throughput assays for T cell detection have been
developed that can utilise these collections of pMHC
reagents. In the following sections we will discuss the tech-
niques that are now available for pMHC-based “high-
throughput” analysis of T cell responses. Implementation of
these new techniques in immunomonitoring eVorts should
enable the measurement of T cell reactivity against hun-
dreds to thousands of diVerent pMHC complexes within
limited patient material; and consequently broaden our
insight into both disease- and therapy-induced T cell recog-
nition.
Detection of antigen-speciWc T cells by combinatorial 
encoding
In 2009, two conceptually similar methods for dissecting
the antigen-speciWcity of T cells by use of combinatorial
encoding were described [4, 5]. We (Hadrup et al.) devel-
oped a technique that uses two-colour combinations of
eight diVerent Xuorescent labels to enable detection of up to
25 diVerent T cell populations per sample. Simultaneously,
Newell et al. published a similar method using all possible
combinations of four diVerent Xuorescent labels enabling
the detection of up to 15 diVerent T cell populations per
sample.
The principle of ‘combinatorial encoding’ used in both
studies relies on the generation of multi-colour codes on the
surface of antigen-speciWc T cells. SpeciWcally, T cells are
incubated with collections of speciWc pMHC complexes,
with each pMHC complex ‘encoded’ by a unique colour
combination (Fig. 1). The diVerently coloured pMHC mul-
timers will assemble on the cell surface of antigen-speciWc
T cells, giving rise to a multi-colour labelled T cell popula-
tion that can be detected by Xow cytometry. By analysing
the colour code carried by each individual T cell it is possi-
ble to determine its antigen-speciWcity. Thus, contrary to
conventional Xow cytometry, in which signal within a sin-
gle channel is used as a measure of reactivity, speciWc com-
binations of colours are used to deWne antigen-speciWc T
cell populations. When only those colour codes are utilised
that are composed of a Wxed number of colours (something
that we consider preferable, see below) the number of pos-
sible unique colour combinations can be described as
K(n, r)=n!/r!(n¡r)!, with “r” being the number of colours
used in each code, and “n” being the number of diVerent
Xuorescent labels that is used for MHC multimer labelling.
We have used two-colour codes (r = 2) of 8 diVerent Xuo-
rescent labels (n = 8) that combine to 28 unique dual-
colour-codes. Of these 28 possible combinations, 25 were
veriWed to be as eYcient in detecting antigen-speciWc T
cells as conventionally labelled PE and APC single-colour
tetramers [4].
Combinatorial encoding only becomes a useful
approach when the number of Xuorescent labels that can
be used is suYciently large (for a two-colour code the
break-even point is at three). To extend the number of
Xuorescent labels used for pMHC multimer labelling
beyond the commonly used PE and APC Xuorochromes,
we have made use of quantum dots (Qdot or QD). The use
of quantum dots in Xow cytometry as Xuorescent labels of
both antibodies and MHC multimers has previously been
described by the group of M. Roederer [6, 7]. Qdots are
semiconductor nanoparticles of cadmium and selenium/
tellurium that have an intrinsic Xuorescent capacity [8].
They are best excited by light at lower nanometre wave-
length (UV to violet nanometre range) and, as the emis-
sion spectra of Qdots are very narrow, they are highly
suited for multicolour Xow cytometry. The currently used
Qdots are Wrst coated with a Zinc-shell to improve their
optical properties, and then coated with polymer to allow
the conjugation of bio-molecules. Streptavidin-coated
Qdots with many diVerent emission spectra are available
and these can be used for the binding of biotinylated
pMHC molecules. We have validated the use of Qdot–MHC
multimers for detection of antigen-speciWc T cells using
six diVerent Qdots (QD565, QD585, QD605, QD655,
QD705 and QD800) [4]. All QD–MHC complexes
detected similar frequencies of antigen-speciWc T cells as
were detected with conventional phycoerythrin (PE) or
allophycocyanin (APC) labelled MHC multimers (albeit
with varying signal intensity). It should be noted, how-
ever, that the eYciency with which diVerent Qdots are
detected is highly dependent on the conWguration of the
Xow cytometry system used.
With the combined use of PE, APC and the set of six
Qdots, MHC multimer staining can be performed with
eight diVerent  Xuorescent labels and the combination of
these  Xuorochromes into two-colour codes yields the
above-mentioned 28 unique colour combinations.Cancer Immunol Immunother (2010) 59:1425–1433 1427
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The main advantage of the dissection of antigen-speciWc
T cell responses by combinatorial encoding is that it allows
the simultaneous detection of (at present) 25 diVerent T cell
populations in the same amount of sample (e.g. peripheral
blood) as is normally required for the detection of just one
T cell population. By increasing the amount of information
on T cell reactivities that can be extracted from a limited
amount of patient sample, combinatorial encoding is well-
suited for both T cell epitope discovery projects and for
the monitoring of immunotherapeutic and vaccination
approaches aiming to induce broad T cell responses.
An additional advantage of this Wrst strategy for combi-
natorial encoding comes from the fact that all antigen-spe-
ciWc T cells are by deWnition labelled with two and only
two MHC multimer colours. Thus, any T cell that is posi-
tive in only one or in three or more of the channels used for
pMHC detection can be deWned as a background event and
gated out. Since most background binding in MHC multi-
mer analysis leads to signals in either one or multiple (three
or more) channels (Hadrup, unpublished observation),
background is reduced approximately tenfold by this gating
strategy. In other words, the sensitivity of detecting anti-
gen-speciWc T cells in a pool of irrelevant T cells is
increased about tenfold through the use of this approach
for combinatorial encoding, as compared to conventional
single-colour MHC multimer staining.
The second combinatorial encoding method for antigen-
speciWc T cell detection, published by Newell et al. [5],
does not rely on Qdots, but uses the PE-Cy5 and PE-Cy7
tandem dyes to extend the number of Xuorochromes avail-
able for MHC multimer labelling. When combined with the
APC and PE Xuorochromes, this allows the generation of
MHC multimers with one of four diVerent labels. Newell
et al. use all possible combinations of these four labels to
obtain 15 diVerent colour codes. Thus, in contrast to our
approach in which all codes have the same number of col-
ours, Newel et al. use both one-, two-, three-, and four-
colour encoding. This alternative combinatorial encoding
strategy has the advantage of yielding a larger number of
colour combinations from a given number of Xuoro-
chromes. However, at the same time it prevents the use of
the above-described gating strategy, and therefore, likely
results in a lower sensitivity.
It is important to note that both combinatorial encod-
ing strategies rely on the assumption that any of the T
cell populations that one aims to detect recognises only
one of the pMHC complexes present within the staining
reaction. If a certain T cell population is reactive with
two diVerent pMHC complexes, this T cell population
will become labelled with all colours used to encode
these two pMHC complexes. When using the gating
approach by Hadrup et al., this T cell population would
thus be gated out as background events (although with
more advanced analysis, a population of cells that does
show a consistent signal in three or four channels could
still be picked up). When using the approach for combi-
natorial encoding by Newell et al., such a cross reactive
T cell population would not be gated out, but would
Fig. 1 The principle of combi-
natorial encoding. Each pMHC 
multimer is coupled to two 
diVerent Xuorochromes (col-
ours), but each colour can be re-
used to encode another pMHC 
complex but now in combination 
with a diVerent colour. The 
resulting pMHC multimers bind 
to TCR complexes at the T cell 
surface, resulting in a two-colour 
labelling of each antigen-spe-
ciWc T cell. Upon analysis by 
Xow cytometry the two-colour 
code is visualised and can be 
used to determine the speciWcity 
of analysed T cell populations
l l e c   T l l e c   T l l e c   T
Assemble fluorochrome
conjugated MHC multimers
Generate collection of 
differentially encoded
MHC multimers
Assembly of combinatorial
codes on T cell surfaces
Analysis by flow cytometry1428 Cancer Immunol Immunother (2010) 59:1425–1433
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incorrectly be identiWed as a T cell population for which the
pMHC is encoded by that speciWc two-, three- or four-colour
combination.
How big is this potential issue? For our analyses with
pMHC sets of a complexity of 25, we have not noted any
instances where such cross-reactivity appears to form a
concern. In line with this, even though cross-reactivity of
T cells is an intrinsic property of our immune system,
required to allow recognition of a vast number of antigens
with a limited number of T cells in the human body, the
chance of encountering cross-reactivity in a sample of 25
unrelated pMHC complexes appears very limited on theo-
retical grounds [1]. SpeciWcally, an estimate based on a
wide range of murine studies indicates that a given T cell
clone can react with approximately 106 diVerent peptides.
Thus, with an estimated universe of foreign nonamer pep-
tides of around 1.5 £ 1010, the chance that a T cell will
cross-react with any randomly chosen peptide is less than
one in 104 [1]. Based on this estimate, the chance of Wnding
cross-reactivity within a set of 25 diVerent pMHC com-
plexes is marginal. However, with the development of
encoding schemes that allow the simultaneous use of larger
peptide libraries this potential problem could become more
realistic. More importantly, cross-reactivity could readily
become a concern when using combinatorial encoding to
detect T cell responses against a set of structurally related
peptide antigens, such as diVerent immune escape variants
of HIV epitopes [9, 10]. In such cases, single colour-encod-
ing could obviously still be used to generate a footprint of
the antigen-reactivity of individual T cells, as has previ-
ously been done for inXuenza A-speciWc T cells [11].
Detection of antigen-speciWc T cells by MHC 
microarrays
Prior to the development of combinatorial encoding, a
number of groups have developed MHC microarrays for
the high-throughput detection of antigen-speciWc T cell
responses [12–15]. MHC microarrays oVer the advantage
of spatial resolution of diVerent pMHC complexes when
spotted or printed on the microarray surface. Upon incuba-
tion, speciWc T cells can adhere to the counterpart pMHC
molecules, resulting in a spatial separation of diVerent anti-
gen-speciWc T cell populations. MHC microarrays have a
very large potential as a high-complexity platform. How-
ever, because of signiWcant technical challenges (see
below) only few T cell monitoring projects have reported
the use of this system [16]. First generation MHC micro-
arrays were generated by direct spotting of the pMHC of
interest onto the microarray slide. More recently, linkage of
pMHC to the microarray surface via deWned DNA probes–
–an approach known as “nucleic acid cell sorting”
(NACS)––has been described [15]. In the latter approach,
nucleotide-probes were designed and linked to streptavidin,
while the complementary sequence was printed on a con-
ventional DNA microarray slide. MHC multimers of a
given speciWcity were then formed using probe-tagged
streptavidin molecules, providing each pMHC complex
with a probe that allows binding to a speciWc site on the
microarray. An important advantage of the NACS approach
is its high Xexibility, since the same DNA-probe array can
be coupled with diVerent panels of pMHC probe-tagged
streptavidin for use in diVerent T cell analyses.
The major limitations of the current MHC microarrays
are their high technical complexity (and consequently low
reproducibility, at least across diVerent laboratories) and
their relatively low sensitivity. Soen et al. have reported a
sensitivity of MHC microarray-based T cell detection of
around 0.1% of CD8 T cells [12]. While other groups do
report higher sensitivities, these are generally still above the
detection limit of MHC multimer-based Xow cytometry.
The main reason for the relatively low sensitivity of MHC
microarrays is likely to be the fact that most systems rely on
the passive diVusion of T cells to their target pMHC. Thus,
many T cells will simply not reach their target, and be left
in solution. As a related issue, if binding is indeed largely
restricted to those T cells that happen to land on a spot car-
rying cognate antigen, the MHC microarray can essentially
be considered a miniaturised multiwell assay system, in
which T cell reactivity towards many pMHC complexes is
analysed in parallel (and in which each pMHC spot forms a
“microwell”). In these cases, MHC microarrays may not
address the issue of sample size to the same extent as com-
binatorial encoding, as this requires each T cell to be
probed for reactivity against any of the pMHC complexes
present within the system.
Of note, a microcirculatory system has been intro-
duced by Deviren et al. and may explain their reported
sensitivity of 0.05–0.01% of the analysed cell popula-
tion, approaching the detection limit of MHC multimer-
based Xow cytometry [14]. The use of microcirculatory
systems is likely to also be essential to allow contact
between a given T cell and any of the pMHC complexes
present within and thereby preventing the “microwell
issue”.
An alternative solution that could improve both the sen-
sitivity and the “microwell issue” is the use of MHC multi-
mer staining in solution with subsequent spatial separation
(a strategy only possible on NACS type systems) or an––at
present hypothetical––“reverse phase” array format, in
which T cells rather than pMHC would be immobilised on
the surface and pMHC multimers would be passed over the
surface one by one. Such an approach would ensure that all
T cells have the potential to encounter relevant pMHC com-
plexes, and serial scanning of the surface by microscopyCancer Immunol Immunother (2010) 59:1425–1433 1429
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would allow one to visualise T cells that accumulate a
newly added pMHC complex.
If the current issues with MHC microarray-based sys-
tems can be solved, MHC microarrays oVer substantial
potential as a platform for T cell detection. SpeciWcally, the
spatial separation of pMHC should support simultaneous
detection of hundreds to thousand of diVerent T cell-speci-
Wcities on a single microarray and the fact that pMHC bind-
ing can be combined with the detection of cytokine
secretion by co-spotting of cytokine capture antibodies
forms a further asset. However, at the current state of tech-
nology development, combinatorial encoding does seem
the preferable strategy for high-throughput T cell detection,
both because of its higher sensitivity and because it pro-
vides a solution to the issue of sample size. The diVerent
high-throughput methods for T cell epitope analysis devel-
oped to date are summarised in Table 1.
Expanding complexity of combinatorial encoding
The number of antigen-speciWc T cell responses that can be
analysed by combinatorial encoding may potentially be
expanded in two ways: (1) by inclusion of new Xuoro-
chromes and (2) by utilising higher dimension encoding
(Fig. 2). Inclusion of additional Xuorochromes is an obvi-
ous way to combine the two published combinatorial
encoding approaches, as the PE-Cy5 and PE-Cy7 tandem
dyes used by Newell et al. may potentially be included into
the eight-colour scheme used by us––resulting in ten possi-
ble Xuorochromes for the encoding of pMHC multimers.
The addition of two Xuorochromes into a two-colour com-
binatorial encoding scheme would enable the simultaneous
detection of up to 45 diVerent T cell-speciWcities per sam-
ple. However, with an increasing number of Xuorochromes,
higher order-encoding becomes increasingly attractive.
Proof of principle has been achieved for three-dimensional
combinatorial encoding [4]. With the use of eight diVerent
Xuorochromes as Xuorescent labels for MHC multimers, 56
unique 3-colour (3D) codes can be created, and with inclu-
sion of 2 new Xuorescent labels, this number expands to
120 (Fig. 2). Ignoring the obvious challenges with respect
to compensation and signal strength for now, two possible
issues should be noted. First, a major limitation of moving
into 3D combinatorial encoding approaches is the diYculty
in data analysis. A select number of Xow cytometry soft-
ware packages, such as FlowJo, support visualisation in
3D. However, these new software additions are at present
not suited for high-throughput analyses. Attempts are cur-
rently made to design new Xow cytometry software that
would allow the automation of Xow cytometry analysis, by
deWning clusters of cells in predeWned colour combinations.
This approach would minimise subjective ‘gating’ of cells
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and would be well-suited for higher dimension (3D/4D)
analyses (personal communication, Dr. C. Chan, Duke Uni-
versity). Second, when moving to analyses with an increas-
ing number of pMHC multimers in one sample, generation
of the mixtures of pMHC complexes may become a chal-
lenge. High-throughput generation of pMHC molecules by
UV-induced peptide exchange (see below) has a concentra-
tion limit of about 200–400 g/mL. When using each indi-
vidual pMHC at a Wnal concentration of around 2 g/mL
this will allow for the generation of pMHC pools with a
complexity of 100–200. Concentration of pMHC multimer
mixes is possible, but often associated with considerable
losses. Thus, with the current approaches for high-through-
put T cell analyses by combinatorial encoding, a complex-
ity of 100–200 diVerent pMHC multimers per sample is
likely to form a practical limit.
“High-throughput” pMHC production
The development of combinatorial encoding for the paral-
lel detection of antigen-speciWc T cells forms the most
recent addition to a number of methods that aim to make
MHC-based analyses suitable for high-throughput screen-
ing. Most importantly, the generation of vast numbers of
diVerent pMHC complexes necessary for multiplexed T
cell analyses has been made possible by the development
of UV-induced peptide exchange technology [17,  18].
This technology relies on the design of a UV-sensitive
(and therefore ‘conditional’) MHC ligand. Upon UV
exposure, this ligand is cleaved and the resulting peptide
fragments will quickly disassociate from the peptide bind-
ing groove. This results in the generation of a peptide-free
(and hence very unstable) MHC molecule that can be res-
cued by the binding of a new peptide ligand. This peptide
ligand can be any ligand of interest, with the obvious
caveat that MHC rescue will depend on the MHC aYnity
of the new ligand [19, 20]. By use of this technology, par-
allel production of vast numbers of pMHC complexes can
be accomplished in a few hours and is feasible in both 96-
and 384-well formats. Structural studies have demon-
strated that the pMHC complex that is formed upon ligand
exchange is identical to that obtained by classical refold-
ing [21]. Furthermore, because ligand exchange takes
place under physiological conditions, MHC reagents can
be prepared with peptide ligands that display only a mod-
erate aYnity for MHC, such as the unmodiWed MART-I
HLA-A2 epitope [17].
An alternative strategy for generating pMHC complexes
was recently described by Leisner et al. [22] and relies on
the high folding eYciency of MHC class I heavy chains
that carry pre-oxidised disulphide bonds. Upon folding of
these pre-oxidised (and already biotinylated) heavy chains
with  2-microglobulin and peptide, the resulting pMHC
complexes can be used for pMHC multimer production
without further puriWcation or concentration. At present,
this method has not been utilised in larger T cell monitoring
studies and such studies will be important to determine its
broader value.
In addition to the use of UV-induced peptide exchange
for the generation of pMHC reagents for T cell staining,
this ligand exchange technology can also be used to mea-
sure the aYnity of putative MHC-ligands in high-through-
put assays. “MHC rescue” after peptide exchange can
readily be measured by an MHC-ELISA that measures the
concentration of correctly folded MHC that remains after
UV exposure. This MHC-ELISA gives a rough estimate of
peptide aYnity, suYcient for most T cell epitope discov-
ery projects and can be performed in both 96- and 384-
well formats, allowing the screening of hundreds or thou-
sands of candidate peptides. Furthermore, a more accurate
measure of the MHC aYnity of a given peptide can be
obtained by peptide exchange-based Xuorescence polarisa-
tion assays, in which competition of an experimental
ligand with a Xuorescently labelled high-aYnity ligand is
quantiWed [18].
A commercially available platform known as “iTopia™
Epitope Discovery System” (Beckman Coulter) oVers an
alternative “high-throughput” strategy for the analysis of
peptide HLA aYnity. The iTopia™ platform relies on
denaturation of a reference pMHC complex followed by
reconstitution in the presence of the peptide of interest, and
the eYciency of this reconstitution depends on the aYnity
of the peptide for the HLA molecule in question. A number
of T cell epitope discovery projects have made use of this
system [23–26].
Fig. 2 The number of possible colour combinations. The graph
depicts the number of possible colour combinations (y-axes) that can
be made based on one-, two-, or three-colour codes, with a given number
of Xuorescent labels available (x-axes)Cancer Immunol Immunother (2010) 59:1425–1433 1431
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A workXow for ‘high-throughput’ T cell epitope 
mapping
The majority of current T cell epitope discovery projects
are based on ‘reverse immunology’. Starting oV with the
selection of target genes of interest (e.g. a viral genome),
potential MHC-ligands within the encoded protein
sequence are identiWed and subsequently, it is established
whether the identiWed MHC-ligands are recognised by T cells
(Fig. 3).
Web-based prediction databases are available to assist
the selection of potential MHC–ligands [27, 28]. However,
depending on the cut-oV chosen, these databases either miss
a substantial number of MHC–ligands or provide many
more potential ligands than actually do bind to the relevant
MHC allele product. The combination of algorithm-based
prediction with a quick screening for MHC aYnity pro-
vides a solution to this issue. SpeciWcally, using a low cut-
oV in epitope prediction will ensure a low percentage of
false-negatives but at the cost of having a high number
of false-positives. When this starting collection is subse-
quently analysed for MHC binding using one of the above-
described binding assays, this can reduce the number of
candidate peptides to 30–50%, providing an important
focus of the peptide library. As the success rate of T cell
epitope mapping projects critically depends on the quality
of the selected set of putative epitopes used for T cell
screening, this combination of in silico prediction and sub-
sequent in vitro screening for peptide-MHC aYnity repre-
sents a useful strategy to focus the downstream eVort on
those peptides that are most likely to represent true T cell
epitopes.
The combined use of in silico prediction, MHC peptide
exchange-based measurement of actual HLA aYnity, and
detection of T cell responses by combinatorial encoding,
has successfully been used for T epitope discovery. In a
pilot project we have used this combination of strategies to
identify new HLA-A3-restricted T cell epitopes from mel-
anoma-associated proteins. Using a low cut-oV algorithm-
based prediction, we selected 256 potential HLA-A3
ligands from four melanoma-associated proteins. Using
aYnity measurements, a set of 22 peptides with the highest
HLA-A3 aYnity was subsequently identiWed, and this set
was used to screen for T cell reactivity in peripheral blood
from melanoma patients by combinatorial encoding. In
this speciWc case, a pre-enrichment step was included,
using PE-labelled MHC tetramers to label antigen-speciWc
T cells and isolate them with the aid of anti-PE coated
magnetic beads, to increase the sensitivity of detection.
Using this strategy, T cell reactivity against eight peptide
ligands was detected, of which three were previously
described HLA-A3 T cell epitopes and Wve were poten-
tially new T cell epitopes. While it remains to be estab-
lished that these new T cell epitopes are actually presented
on the surface of tumour cells, this pilot screening project
demonstrates the feasibility of high-throughput MHC-
based screening projects for the identiWcation of novel
T cell epitopes.
Conclusion
‘High-throughput’ approaches for T cell epitope discovery
and monitoring, have the potential to signiWcantly improve
our understanding of disease- and therapy-induced T cell
reactivity. The human body holds approximately 2 £ 1011
diVerent T cell clones, and T cell recognition of pathogen-
derived or cancer-associated epitopes is therefore likely to
be complex [1]. A glimpse of our lack of understanding of
Fig. 3 Schematic overview of ‘high-throughput’ T cell epitope map-
ping. The combination of three MHC-based technologies. a the gener-
ation of pMHC complexes by UV-induced exchange of a conditional
MHC ligand. b Peptide-MHC aYnity screening by MHC-ELISA.
c T cell detection by combinatorial encoding, together forms a
high-throughput platform for T cell epitope mapping by ‘reverse
immunology’
Select genome
of interest
In silico epitope
prediction
Select true 
MHC binders
Create a panel of 
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combinatorial
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the breadth of T cell reactivity becomes apparent when
analysing the MHC restriction of the epitopes identiWed to
date. For both infectious disease- and cancer-associated
epitopes, a very strong bias towards restriction by the dom-
inant HLA alleles in the European and North-American
populations is apparent. As an example, a compilation of
the melanoma-associated epitope set described to date for
the HLA alleles A1, A2, A3, A11, A24, B7, B57 that we
performed for a planned immunomonitoring project
revealed that about 70% of these epitopes were restricted
by a single HLA allele, HLA-A2, which is the most preva-
lent HLA allele in the Western European population (Had-
rup SR, unpublished data). Thus, there is a clear need for
the identiWcation of T cell epitopes restricted by other
HLA-types, as 60% of the Western European population
does not express HLA-A2, and this number is even sub-
stantially higher for all other populations.
A broader knowledge of the disease-associated epitope
repertoire is likely to be particularly valuable when moni-
toring T cell responses induced in a non-HLA restricted
fashion. To provide two speciWc examples, treatment of
patients with metastatic melanoma with ex vivo expanded
tumour-inWltrating lymphocytes has shown highly encour-
aging data in a single centre study [29, 30] and anti-CTLA4
is currently in phase III trials for the same patient group
(ClinicalTrials.org: NCT00636168, Bristol-Myers Squibb
and NCT00257205/NCT00584493, PWzer). While in both
cases clinical eVects are likely to be mediated at least in
part by CD8 T cells, at present we have very little informa-
tion on the antigen reactivities involved. With the develop-
ment of ‘high-throughput’ T cell epitope mapping
approaches we now have the tools to obtain a more compre-
hensive view of antigen-speciWc T cell recognition that
forms the basis of these emerging therapies.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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